Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. Co. is focused on developing therapeutics for patients with immune-mediated diseases. Co.'s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial. We show 6 historical shares outstanding datapoints in our CLYM shares outstanding history coverage, used to compute CLYM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CLYM market cap history over the course of time is important for investors
interested in comparing CLYM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CLYM versus a peer is one thing; comparing
CLYM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CLYM can fluctuate over the course of history.
With this page we aim to empower investors researching CLYM by allowing them to research the CLYM market cap history. |
Free CLYM Email Alerts:
Video: The Importance of Market Cap
